AdamNo_L

Overhyped or overlooked? Technical Analysis.

Short
NASDAQ:PACB   Pacific Biosciences of California, Inc.
PACB is on a tear right now with new of an acquisition deal by their competitor Illumina for 1.2 billion dollars. According to Forbes, this is the largest deal Illumina has ever made in more than 20 years. According to other reports the deal won't be finalized till mid-2019 though, so today's price increase seems to a result of that new breaking yesterday after hours. The other news surrounding PACB however was less bullish. Their recent earnings report had investors at a loss.

Metric Q3 2018 Q3 2017 Change (YOY)

Sales $18.2 million $23.5 million (22.9%)

Net income (loss) from continuing operations ($25 million) ($22 million)

Earnings (loss) per share (EPS) ($0.19) ($0.19)

From a technical standpoint, I'd wait to go long here. The run up stopped right at the edge of the ichimoku cloud which indicates to me that the there was a decent amount of speculation involved in this price run up. Curious what others are thinking.

Share you thoughts.
Thanks.



Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.